FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970006516> ?p ?o ?g. }

• W1970006516 endingPage "435" @default.
• W1970006516 startingPage "428" @default.
• W1970006516 abstract "Abstract: Endocrine abnormalities in patients with chronic renal failure are well documented. The present study aimed to assess the influence of long-term erythropoietin (EPO) therapy on endocrine abnormalities in hemodialyzed patients. Two groups of hemodialyzed patients, each of which comprised 17 subjects, were examined. The first group was treated by EPO (EPO group) while the second one did not receive this hormone (No-EPO group). A complete biochemical and hormonal check-up was performed before and at the 3, 6, 9, and 12 month points of the study period. Normal values for the estimated parameters were obtained in appropriately selected sex- and age-matched healthy subjects. After EPO therapy, an increase of the hematocrit value from 21.8 ± 0.9 to 32.6 ± 0.9% was observed, which was accompanied by a significant decline of plasma ferritin and saturation of transferrin. In patients of the No-EPO group, a significant although less marked rise of the hematocrit value (21.4 ± 0.4 to 24.2 ± 0.6%) was also noticed. EPO therapy did not change plasma levels of electrolytes (Na, K, Ca, inorganic phosphate), osteocalcin, creatinine, glucose, and alkaline phosphatase as well as plasma concentrations of calcium-related hormones (PTH, calcitonin, 1,25[OH]2D3), vasopressin, and triiodothyronine. EPO treatment induced a significant decrease in somatotropin, prolactin, follitropin, lutropin, ACTH, cortisol, plasma renin activity, aldosterone, noradrenaline, adrenaline, dopamine, glucagon, pancreatic polypeptide, and gastrin plasma levels and an increase in plasma insulin, estradiol, testosterone, atrial natriuretic peptide, thyrotropin, and thyroxine. These EPO-induced endocrine alterations were restricted mostly to the first 6 months of EPO administration. In patients of the No-EPO group, a significant decrease in the plasma levels of prolactin, noradrenaline, and dopamine and an increase of estradiol plasma levels were also noticed during the 1-year study period. Therefore, long-term treatment by EPO shows profound effects on the function of several endocrine organs. These effects are transitory and predominantly restricted to the first 6 months of EPO therapy. Not all endocrine alterations observed in EPO-treated patients seem to be due to the administration of this hormone." @default.
• W1970006516 created "2016-06-24" @default.
• W1970006516 creator A5008321452 @default.
• W1970006516 creator A5009674344 @default.
• W1970006516 creator A5013861060 @default.
• W1970006516 creator A5016489911 @default.
• W1970006516 creator A5035451079 @default.
• W1970006516 creator A5042539798 @default.
• W1970006516 creator A5044605455 @default.
• W1970006516 creator A5049869761 @default.
• W1970006516 date "1995-05-01" @default.
• W1970006516 modified "2023-10-14" @default.
• W1970006516 title "Function of Endocrine Organs in Hemodialyzed Patients of Long-Term Erythropoietin Therapy" @default.
• W1970006516 cites W120300225 @default.
• W1970006516 cites W1928423338 @default.
• W1970006516 cites W1963736315 @default.
• W1970006516 cites W1981079465 @default.
• W1970006516 cites W1986999259 @default.
• W1970006516 cites W2041907052 @default.
• W1970006516 cites W2046773795 @default.
• W1970006516 cites W2067548529 @default.
• W1970006516 cites W2078428667 @default.
• W1970006516 cites W2078467811 @default.
• W1970006516 cites W2156399445 @default.
• W1970006516 cites W2185012131 @default.
• W1970006516 cites W2211219753 @default.
• W1970006516 cites W2253774521 @default.
• W1970006516 cites W2256155501 @default.
• W1970006516 cites W2266902307 @default.
• W1970006516 cites W22852907 @default.
• W1970006516 cites W2292321753 @default.
• W1970006516 cites W2302952525 @default.
• W1970006516 cites W309190426 @default.
• W1970006516 cites W564296250 @default.
• W1970006516 cites W2283298920 @default.
• W1970006516 doi "https://doi.org/10.1111/j.1525-1594.1995.tb02354.x" @default.
• W1970006516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7625922" @default.
• W1970006516 hasPublicationYear "1995" @default.
• W1970006516 type Work @default.
• W1970006516 sameAs 1970006516 @default.
• W1970006516 citedByCount "41" @default.
• W1970006516 countsByYear W19700065162012 @default.
• W1970006516 countsByYear W19700065162014 @default.
• W1970006516 countsByYear W19700065162015 @default.
• W1970006516 countsByYear W19700065162016 @default.
• W1970006516 countsByYear W19700065162017 @default.
• W1970006516 countsByYear W19700065162018 @default.
• W1970006516 countsByYear W19700065162020 @default.
• W1970006516 countsByYear W19700065162021 @default.
• W1970006516 countsByYear W19700065162022 @default.
• W1970006516 crossrefType "journal-article" @default.
• W1970006516 hasAuthorship W1970006516A5008321452 @default.
• W1970006516 hasAuthorship W1970006516A5009674344 @default.
• W1970006516 hasAuthorship W1970006516A5013861060 @default.
• W1970006516 hasAuthorship W1970006516A5016489911 @default.
• W1970006516 hasAuthorship W1970006516A5035451079 @default.
• W1970006516 hasAuthorship W1970006516A5042539798 @default.
• W1970006516 hasAuthorship W1970006516A5044605455 @default.
• W1970006516 hasAuthorship W1970006516A5049869761 @default.
• W1970006516 hasConcept C126322002 @default.
• W1970006516 hasConcept C134018914 @default.
• W1970006516 hasConcept C138976137 @default.
• W1970006516 hasConcept C198710026 @default.
• W1970006516 hasConcept C2778525890 @default.
• W1970006516 hasConcept C2778534260 @default.
• W1970006516 hasConcept C2778563252 @default.
• W1970006516 hasConcept C2779064019 @default.
• W1970006516 hasConcept C2780959883 @default.
• W1970006516 hasConcept C46699223 @default.
• W1970006516 hasConcept C71315377 @default.
• W1970006516 hasConcept C71924100 @default.
• W1970006516 hasConcept C84393581 @default.
• W1970006516 hasConceptScore W1970006516C126322002 @default.
• W1970006516 hasConceptScore W1970006516C134018914 @default.
• W1970006516 hasConceptScore W1970006516C138976137 @default.
• W1970006516 hasConceptScore W1970006516C198710026 @default.
• W1970006516 hasConceptScore W1970006516C2778525890 @default.
• W1970006516 hasConceptScore W1970006516C2778534260 @default.
• W1970006516 hasConceptScore W1970006516C2778563252 @default.
• W1970006516 hasConceptScore W1970006516C2779064019 @default.
• W1970006516 hasConceptScore W1970006516C2780959883 @default.
• W1970006516 hasConceptScore W1970006516C46699223 @default.
• W1970006516 hasConceptScore W1970006516C71315377 @default.
• W1970006516 hasConceptScore W1970006516C71924100 @default.
• W1970006516 hasConceptScore W1970006516C84393581 @default.
• W1970006516 hasIssue "5" @default.
• W1970006516 hasLocation W19700065161 @default.
• W1970006516 hasLocation W19700065162 @default.
• W1970006516 hasOpenAccess W1970006516 @default.
• W1970006516 hasPrimaryLocation W19700065161 @default.
• W1970006516 hasRelatedWork W1967336868 @default.
• W1970006516 hasRelatedWork W1969858557 @default.
• W1970006516 hasRelatedWork W2012977668 @default.
• W1970006516 hasRelatedWork W2027429917 @default.
• W1970006516 hasRelatedWork W2070582595 @default.
• W1970006516 hasRelatedWork W2080723551 @default.
• W1970006516 hasRelatedWork W2104119616 @default.
• W1970006516 hasRelatedWork W2177682625 @default.

• next